Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPYVJuRXNERFFCcWtPcDAtM2ZsXzdzT2FLbkg5elc1aGVpTjFqWl9HaGM3SEMyN19Ub1k5QTNqcjh4MHFCVE1iRTFPbjh1ODBKQUlLaFdnSFlaLUVPd0N5VDNYOHc4Zmh5ZzllSGxEb1RfalNreC1jc2J3azZleHhERGRVbm9DRENVdWtBZXBjaTNyU05WdXVUZVc1cExEOEo3elNZcmZFakN0dkVZa0FZa2ZR?oc=5" target="_blank">A faster route to rare disease treatments: the MHRA’s proposals</a>&nbsp;&nbsp;<font color="#6f6f6f">The Pharmaceutical Journal</font>
GameStop Stock Hits a New 52-Week High: What's Going On?
The Myth of St. Francis
Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League
The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBWVFBZbS16RUk3ZERhbnVfS28zUTh6ZDhFT1ItaEtHNnJwSEluM2hkNVZCTzA4Q3hLLTd6d2tpd2otOEY5empqS2VwMUs4Zy1TQ2FfNTYtQ1RLQ3F0NmZhZWdGd1BDcjBxQWxhZA?oc=5" target="_blank">The New Capital of Care in Rare Disease</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Executive</font>
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQS1NaMFE4UC05ZkkxdzVxNG1qdkJfY1M5dmJaVDNpNkNDaTBUOUZ6VWNFMGRfMUhzc1JYa3E1MGpobEZsMHRtM1I2UjkxZzMzZFN1R2Z2OHBqSE1hR21jbDlQVUFBT3JRdlhvRE16RFh1S21PUXJmbmhTRUNxZko4Nzl3eFRWQUJmYXVCRm5hREd1RWJjVExXSFJVVWpPOThhLWxN?oc=5" target="_blank">BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases</a>&nbsp;&nbsp;<font color="#6f6f6f">Yahoo Finance</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPN3dxSy1BNnlobElNX2ZKd3hYcTBUM25XMnkzMkl5dkVwUkFLNHdBLU5wS3VZVkc0dDlCejdpdjN6UEdoXzM1RnF2Yi1yYUhyeWhXdVE5alVmOUUwLVlKZGExOFMwZ0MyVkgtSHdsbUhpSFYwc2twUjV0eTFLWHdSS0tqbGtMY2xDWHNsUTU2ek9US0txQk5JMmpXRWZrc1RHVzVEbG9BSDVURWxEblIw?oc=5" target="_blank">Insights From Fellows in Rare Disease: Navigating an Ultraspecialized Space</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmacy Times</font>
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPdjRJcnFOYldjVHlvTkRkMUxJdGNRQ0VGdjhwcks2TXFhUEtJT2hVNENGSTM4T3lxSVlSdE94dUFadXprMG41YzFEYllvRVAzSm9waG5uY0RzblcwY1M2RC03QjViWnA4Ni1zUE5yZ2QzVkJOREJwWWkyMzFPdDMwdVFWNnhNdmlIMTlQdUZDTQ?oc=5" target="_blank">Building Durability in Rare Disease Care With PANTHERx Rare</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Commerce</font>
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNa25XQ3dEaTZZa284SG5MMVE1UjRwdzdHNjZpNUd3bU5KY2xsZVpRUl9DZDR4MDR3QTFXbEVhQkxla2tYY3drU1Q0TlJpQVZWanFkSC05WkgyeXhPOUtUM1BjMWVDX21jUEd4WVJVakJDVnlCY3N2Y1FOMkVJaWt0YjVBdHl2Wmhx?oc=5" target="_blank">The Rare Journey Needs a Special Pharmacy Partner</a>&nbsp;&nbsp;<font color="#6f6f6f">Drug Channels</font>
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNOGV0ejd4by1sX2VvYjMtUE9TWnpuNXhYNUt1bzl2T2ZGQmNiNGxlbEk3LW5Dd0ZTeW1LNnp0V3Yxb1J6WHoweTd4UWl3ZDJZN3R5THpsdW82Q0xvOGVxNjZsQWdNbFRNWHIyNGZrWG8zSGZ4Y29FN21BNnhBUkQ0bmQxQTVVWHFmZ3Bj?oc=5" target="_blank">Japan pharmaceutical firm warns against rare diseases drug after deaths</a>&nbsp;&nbsp;<font color="#6f6f6f">Medical Xpress</font>
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPMGd2MUdfQzlLeGVLa1J5VEt4c3lxQWZ5OVVGR1ROOGFoVk1iQzl6Umc3V290TWczMUc2ajBfWUwtekl5WHd4OUpZNExUSmZlNjI1OG5lbEJIOUJaTm9RTVR4S1hCSXpTYnF0R1lkREVIUm4zQmtLOGZVdXVSUzFHZ0FydDJLeXRDOE5KZXlKb2dGQUVrTTEzZnZnbldBY29rN1E?oc=5" target="_blank">Rare Disease Treatments: Navigating the Economics of Global Innovation</a>&nbsp;&nbsp;<font color="#6f6f6f">PharmTech.com</font>
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNbWQxQUtDNDhSaUZwLThjamNhdkx1OS1pMmdVbTZOZkZoZlBWT0tGVWRWRnljTTFlOHNtcDVaUG1FNVhhbmxZNk9KR0FzbldpdUI3V0xTNV9HU2cxQ2xnTEFNWlhPRWZTXzZNbHdTVHVXSWJoMnRseFZLTDNnTmwtWWU4VEpOSjJKV3dMajlBYmlpODZNTFBDdXBTYXRqS1h5NHRVOUJDUGhsdU1pTnVsal9QRTFTOTVnNWkxWg?oc=5" target="_blank">Orsini to Serve as Specialty Pharmacy Partner for Priovant’s LISRAYA™ (brepocitinib)</a>&nbsp;&nbsp;<font color="#6f6f6f">BioSpace</font>
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPclhvUFVRX0NiZk1DNDY4cVNSRlZGTmdLVHp0Ny0wLWJjUk1NQWRuWnBfUHB5TTNZX1lrR2dZOFRKSDc0QmktSUlCUmNVeERsMFdpS0FvWGMwdzl5QjFLSTdpUG5qcGJVMm9McmkydUMzM0hScEp2MkZZMlB5VUZiaVo0cVR4cENaT1hrZV9PaDY0b1RzQWJnUTd3TVVVQUZ2VkE?oc=5" target="_blank">Slow progress as rare disease regulations in developing ASEAN states begin to take shape</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Technology</font>
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPQ2dxb2xoaTllLW9CcjFtUnMzNEhlLVIxNEc5UHJWblIwdEl6dEpXamF5SXZtY3JFdGFIOHZ6dFRES29HX3FZRXlYejFGYi0zclhHWUlzTERfTmViNGY2VzU5Z2dPWUhsUUJDYVR3YVZYbUVQMzVXQy01VW1CcUZYcF9xMFhrTHVSdHVfcHg1WTN0Ml84TEUwQTgzckJzQjdKMnJRX0Q5WTd4OS1hYTU4cWlnQjVndWFxTjEtTXlpamJEMmlwZ0MyZldsRUs5SEhVLXNnQjdUaHd4eUdGRmFtVmpjcDhpMjJiME5nUA?oc=5" target="_blank">Building Resilient Rare Disease Support in Malaysia with Pharm-D Health Science's VALENS Specialised Nutrition</a>&nbsp;&nbsp;<font color="#6f6f6f">Plataforma Media</font>
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQUXhLZG8tQk9xOEozejZJQmtIdC1NWDd2T2o4Mm0zZ0FPQy1TMTAzUTR4SDNiamtKdDhfdjBXZVZWazBPV09CbFpqVFpJcXk4QkpoODBZLVdobVllcnJXX3BlY21hZGY4Y0ZmdnJvS0VxdEpyNG1YRF9NTERuS2hlVmVXM2p2Ml8wdDRtVGMtaU9MUTY3OUtBVmQxSW5wYTVSd1RKeDJEd082dHYzdTM2ODRaejhqTjQ?oc=5" target="_blank">The Hard Truth About Rare Disease and Gene Therapy Drug Development</a>&nbsp;&nbsp;<font color="#6f6f6f">Applied Clinical Trials Online</font>
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQTjctcnJZaU1fR0dLYlZselhtSC0yYmJhbFZBRklENzNIdzZPcU9INW5rRXBub2dVTGdrNkxEUTlWdVNYSnBtTTN1emlyUlZtc3hCT1c0WDRfdUVGT2U4NnZZUno1WGtTd01WR01ZS1d1Q3hoVUhiTGJwTTBEdmJ5aFJIUWlMd0E0VmlFRmxhLUY?oc=5" target="_blank">Women in STEM: Unique Impacts in Rare Disease Development</a>&nbsp;&nbsp;<font color="#6f6f6f">PharmTech.com</font>
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQaHlfYjBzR011VS1vVkVxWDYtWmpPWE91ZExpY2ZQdXJ1a1dacWVTWlczUUJwa0ZFTUVTREs3MjlwOEEyVm5NWkZleHZpZklHdFItbWI1NGg4WmpLZ3FCcjZSR3FDalh4SUNkQUoxbnhYLTA4T21FM2s0M0xuUGNLYUZaX2pfdFVjQWExcmF2eWI1NkdS?oc=5" target="_blank">Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE94TF9ULWh2Tk1sTGU5ZGVvUHhNaHBidThDc1M1ZE1fZTFMQ2tiMVdNT3M3TTJuSzllaklIRWw5ZzdqNHZZbWk3Wk96dWxXWXhCMHRoSl9NdFhYVUt3X3I0NENySGEzQlNYTnR6REtyRGdyZzJZdkNB?oc=5" target="_blank">Immersive Patient Advocacy: Q&A with Amy Grover</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Executive</font>
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNcWc4MlNVUjNIUzRja0szUnV2Mjc5Z3llYVNJSHRJSDJTZnVVZG9JRS1KbGlmOHBseXJIN21Xdy12Q2VoTTZ6YmQxNFZUQ0ZpOEhwYnpseHJ5TFA0STllNzZ2bHd0SnhadHVoZzI5eHliS2ZIM2g1VDJxRm9wb0lDU09DM3NBeEV5T2V2SnRpUzVHaC1mVW1vTDRUNVJXUmxQTHEtUWxpVkFSbnZYU2tPdFRhTjV3VEU5ZlE?oc=5" target="_blank">Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Technology</font>
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQQ2hvdmM2czdkallWakt5LUUtcVFoTUVVZ19Ya2VfZkJCVkRKNV91LS1WYmxtbGh5VmxuUTZORmVQeWJrTnJJZnlPdXV5aFFYanBuYVlYaXlDUUl1RGFaUUo5Z1Z5WHdDYm1OaUF2QkhlSE51OXZQWTl3TTlDQ3Z3blJoaGQ0Uzlx?oc=5" target="_blank">Inside Rare Disease Pharmacy: Lessons in Personalizing Care</a>&nbsp;&nbsp;<font color="#6f6f6f">Drug Channels</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPRkZGQTUtcWVqNi1rZlZJTk1rSGNubkhfUy00dmgyMTd5cGdtQU5iM1JIM2xxV29aMWMySG1VTUtsMXdGdVYxcl9EMzdxYmtZeU8wTklDRkxwY3l5VDFiTzhvRnl1X3NLbmVFSDBtR1YzOGh2aHptM2htVmRreGlod1lFY3F6TE9xczNwSi1jdzF0dw?oc=5" target="_blank">FDA prevails over EMA in 2025 novel drug approvals</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Technology</font>
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQUnhYUXl5VDRIN2l0c0lOVEtYNWlMNW16RjdRVTJ6eW5rV19PUFQwU3p6eG9VSXJyYWZweVJESE1mUVpETHVPMnF4MzlILTZsZ2poV0F0bVcwcWZaTXNwZGdrZ3QybC15bUtTSndiekZVWHlrbFlMMUF6VGxQcHd6VmJhd0c?oc=5" target="_blank">Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner</a>&nbsp;&nbsp;<font color="#6f6f6f">Drug Channels</font>
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQNnV4b0NGN1ZBbUxuUWtGTXJkNFBVNVZkY2c5VldhTmFETWFaMW00VkJIaXc3VmU3emlCbjdPQ0JmOWluZGtXdVlrRjVkSVd3dDdwV3hYQlItakc5a3Bna3E4NkdnM3FhM3BNWjJ2anhQcy1ubnp0ZE50a2hiRGVQRHJIdlVEbTRlWS04cA?oc=5" target="_blank">ROI and Rare Disease: Retooling the ‘Gene’ Value Machine</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Executive</font>
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNZzFYTldWSzNydDhyUW5qSEhQNnJUVVhlemtLZnhBMWNBV2NLWlFEYTh0TmxCRXlVVWZtOFVWZXp6RjJEM05Oa0Uyc0RKd0FMeDdXT0p6d1lWYXp6NTRxYTJ0TTNkLVpOVVY3XzA5R3cxZHZ1UExvY1AzbmFpWTUycUk2VFVKR2VVX1R6OGZSd1RneGRBVmE1dnNDemt3Q2Naa0NzQUhGWVZ6dHFsYlNkOGZyQ3VITmQ1TkRmZG13?oc=5" target="_blank">Rare Disease Pharmacies: The Quarterbacks for Orphan Drug Regimens</a>&nbsp;&nbsp;<font color="#6f6f6f">Specialty Pharmacy Continuum</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQkh3UndwcV95MkxUTVFpOG5HczNNN3l0bHNLakRzaEVQTl9QVVNHdlJJcWVZMU1hYk5LMlNRekhZT0NFdWxCWHp2Unp2bzJ3QnBvOFdiR29lZlpWSTF0MnFHbGg5YW9idmtIZ2NzUXRWVXJabEVoYWFvYkVuRW9leWg0VWJQRjdsMkNaU3UyNmxieGdSbElVLTR4TGIwNG05NVNVN1ZtTEpMLV9JYjE1OVpQWGozQVY2WEVmRFZGNUg?oc=5" target="_blank">Pharmacy’s Role in Treating Rare Disease: Connecting Patients, Providers, Payers, and Pharma</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmacy Times</font>
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQRVd3SDVGTVlGVmJaUXV3eXBZbmRnOUdoeGR6eG9ncnREc3dTcWhIb0QyalV6OTZ5ZDlBTWFaTnJxSUItYWlDT1JDMXh4WXJCbnJfNUdISGIwYzVYNHRXaHlwbzJTRVZXZGlhUnZ4dDBEMzJEUFRrUk5mcXBFRjVYY0l2emtrRGtnbDc4S2VhZUJ4MldoRDJnMlVMRnM5Ykd6VnRLaXEwZmhNU254NVQyQjdlR1hQVTk1ekVxOG9EMA?oc=5" target="_blank">How Health Systems, Pharmacy Teams Tackle Rare Disease Therapy Barriers: David Mitchell, PharmD, MBA</a>&nbsp;&nbsp;<font color="#6f6f6f">AJMC</font>
<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE1Qb2h3M2lEWFBrQ19oQy1EN05IZjBiUlBCUzFiME90TmJwY1J0ZmpQc2g5VU9CQ01zWEVJTWlyV3VYb2tTNENaY1BVUEtpbzdCVGxOMnBxbFZaUU8zVkE4VnkzYzh5aEJydnc?oc=5" target="_blank">Therapeutic Orphan No More: Role for Clinical Pharmacology and Translational Science in Developing Therapeutics for Rare and Neglected Diseases</a>&nbsp;&nbsp;<font color="#6f6f6f">Wiley & Sons</font>
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNajZEZGFEb0xjQzdaY0pELXJpUGZTLXRZRkZKV2huR0RSWGVYMkM2b2JNN1Y1X3U1S1J1cTdqRnB6bVBKdXZyTnZUR0hURDB4X2tJb2RqbjR3MEFURWRqV1VBVzh4WW9fWnc1WXBfREJRZE1ocnhZMFNtZjQ2TUZaU2oxTVlUNDlZTEtFT2hWUFNSUmJq?oc=5" target="_blank">Reframing risks in rare diseases: economics of networks, spillovers, and scale</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNS2dwVHR0dzVKdmY0NTBMVGt4cGUzZ1poeFRKZ3Fnbm9IMVJoM1JwOTFWc1ZDU3hKMU5JSkNSOFJIUWRaaUNhcm1PaHdzU3lfNWN3dDU3MVFuYV9rNFduTHpJT1lCMmY2NEw2YlBNZUVPR2FRNjFxdjZvUlNQVmItX1BQMFRHVUlQVHRhRVREaFFPcWhqRXE1ZTkzT0QwUm1vM0pCODRoX203bmpjTkZPdG8wVVF6RVJHZUhUYU92cDBLdGJaV0JkdWhnaDQ2WGdHcE4ybThLNDhseUpY?oc=5" target="_blank">How FDA Incentives and Patient Advocacy Accelerate Rare Disease Drug Development in Biopharma (Part 2)</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharm International</font>
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQLTFIb3pGU1Uyczc1bHpHNW82YjgyV2FzU0ZxRURCMHRKckFyXzhTNXB6SVpHUUYtcU5KQVNlelR5U1VkcGdLMVpNc0NiOWZ2dzRDa204UFU1Zi1jYjZ3X0RHXzNlOWVIc2c5QlRzZ1dVM05tYkZlRzRhSDlzM1d1ZnpIQ091M290aEF3U1dPM0QwbmREY2hpaTFiSERKX3hXX2h2WjR0bHhGamc3aGh4ajB3?oc=5" target="_blank">Understanding the complex rare disease and specialty pharmaceutical landscape</a>&nbsp;&nbsp;<font color="#6f6f6f">pharmaphorum</font>
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOVElTVzRYYkQyQnQ2UGhLcW53TXpXbV92QWl2cFFESVRhZWQ3T2padGNTTTF1Q1lnTEYyWHZRM0Y5Z2JfUUpMOXRXRWpXdzVYV241QjhDQjkySHM2TEFudkVaRElkam9KTUYyY1A1cmxEOF9td1o4VkR4b3ZoSG1NdERScnBfNUE2clIyd0FuaU95TTBTc2gyWnRubUxpNGFDNlhxQTdzS2RmcFExUk1DSWQzRUN2cGUtYTNVR0VQcS1RbGhMVW8xTHpqdjEycG15Z1UyT2RCdW9NTmpyV2o0anp2MFdFV25YMXpkMnJZaXQ?oc=5" target="_blank">As Rare Disease Drug Approvals Accelerate, PANTHERx® Releases Research on Strengthening Care Coordination</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNMURmamZ3VXZ3WGh0czJKQmFxUTFRcjRWT1JUZXhmSUVWX3hzTUthd242cE94T3p4VHlSaFc1OWNPSlFZXy1ZTUY4VWUxdVg4R3VUdUJkNjZYOG5HWjBzWmdVWnFESXI3ejNmeWxXUWxQU3l1UmRyUEdOTU9XRmdYWEtEdTh2NG8?oc=5" target="_blank">US Spending on High-Revenue Rare Disease Drugs in 2022</a>&nbsp;&nbsp;<font color="#6f6f6f">AJMC</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPZmZkVVlEUGJoQ1E1ZXhaUEc1ZGp1ZjdQUERmQkJob2tIRDUzU3lVTjRKaHVqb1Jwd0ZFbEtGRXZGRkJDdXFTMWpJOG1SblN0dTJkYlI5cDdic05tZm5jZXo2YWpybE1FUEZNZm5CdFctQ20xUHZlb25wVHltMkoyM0ZLU0o1SW8yX3lSQm44SEVEbzJJWXo3R3F3YnIzS21hOUM5ZVRwVjk?oc=5" target="_blank">Left in limbo: When pharma halts rare disease research</a>&nbsp;&nbsp;<font color="#6f6f6f">Pharmaceutical Technology</font>